Ex-Geron Corporation CEO Launches Effort to Revive Lost Stem Cell Program

The world's largest embryonic stem cell research programme could be given a new lease of life. In 2011, biotech giant Geron announced that it was closing its stem cell programme, even though it had conducted a decade of research and treated four people in the first clinical trial of human embryonic stem cells (hESCs). Now, Geron's former chief executive Thomas Okarma, and founder Michael West, have joined forces with a new subsidiary of BioTime, a biotech company based in Alameda, California. Together they have put forward a bid for Geron's stem cell assets in an effort to revive the programme. Meanwhile, the four volunteers that received hESCs for spinal injuries are being monitored for adverse effects by the California Institute for Regenerative Medicine in San Francisco.